[Prognosis for therapeutic effectiveness of radiotherapy in the combined treatment of cancer].
The efficacy of radiotherapy and chemoradiotherapy for patients with breast cancer and combined treatment for bladder cancer was evaluated by means of as-blood test (Sbl). It points to magnitude of radiation-induced decay of peripheral blood DNA in vitro prior to therapy. Level of DNA decay was evaluated after exposure to 2Gy and 3-hr incubation. The index in excess of 1.0 (in radiation-sensitive patients) was followed by a relapse-free survival 1.5-2 times longer (5-32 months depending on pathology) than in radiation-resistant patients. Also, a relationship was established between Sbl index and leukopenia level, as an indicator of hematoxic effect of radio- and chemotherapy on patients with bladder cancer and Hodgkin's disease. Hence, Sbl may be used to individualize a therapeutic modality including radiotherapy and, if necessary, to provide for use of hemostimulators.